UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

The New England journal of medicine, 2021-06, Vol.384 (23), p.2187-2201

2021

Volltextzugriff (PDF)

Unbiased identification of risk factors for invasive Escherichia coli disease using machine learning

BMC infectious diseases, 2024-08, Vol.24 (1), p.1-12, Article 796

2024

Volltextzugriff (PDF)

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2388-2395

2013

Volltextzugriff (PDF)

Tutorial in biostatistics: the self-controlled case series method

Statistics in medicine, 2006-05, Vol.25 (10), p.1768-1797

2006

Volltextzugriff (PDF)

Distribution of extraintestinal pathogenic Escherichia coli O-serotypes and antibiotic resistance in blood isolates collected from patients in a surveillance study in Japan

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022-11, Vol.28 (11), p.1445-1451

2022

Volltextzugriff (PDF)

Harmonizing the collection of solicited adverse events in prophylactic vaccine clinical trials

Expert review of vaccines, 2023, Vol.22 (1), p.849-859

2023

Volltextzugriff (PDF)

A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies

Biometrics, 2016-09, Vol.72 (3), p.877-887

2016

Volltextzugriff (PDF)

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

Journal of adolescent health, 2007-06, Vol.40 (6), p.564-571

2007

Volltextzugriff (PDF)

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

Human vaccines, 2009-05, Vol.5 (5), p.332-340

2009

Volltextzugriff (PDF)

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI

npj vaccines, 2024-06, Vol.9 (1), p.106-9

2024

Volltextzugriff (PDF)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

npj vaccines, 2022-11, Vol.7 (1), p.156-156, Article 156

2022

Volltextzugriff (PDF)

A Nurse-Led Interdisciplinary Intervention Program for Delirium in Elderly Hip-Fracture Patients

Journal of the American Geriatrics Society (JAGS), 2001-05, Vol.49 (5), p.523-532

2001

Volltextzugriff (PDF)

Adjusted significance levels for subgroup analyses in clinical trials

Contemporary clinical trials, 2010-11, Vol.31 (6), p.647-656

2010

Volltextzugriff (PDF)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

The New England journal of medicine, 2022-03, Vol.386 (9), p.847-860

2022

Volltextzugriff (PDF)

Testing Treatment Effect in Randomized Clinical Trials With Possible Nonproportional Hazards

Statistics in biopharmaceutical research, 2017-04, Vol.9 (2), p.204-211

2017

Volltextzugriff (PDF)

Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic Escherichia coli Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies

Clinical infectious diseases, 2023-02, Vol.76 (3), p.e1236-e1243

2023

Volltextzugriff (PDF)

Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial

The Lancet infectious diseases, 2019-06, Vol.19 (6), p.631-640

2019

Volltextzugriff (PDF)

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2018-07, Vol.19 (7), p.916-929

2018

Volltextzugriff (PDF)

Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60 to 85 years in a randomized, double-blind, phase 1 study

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2024-09

2024

Volltextzugriff (PDF)

Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections

Vaccine, 2020-07, Vol.38 (33), p.5100-5104

2020

Volltextzugriff (PDF)

Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study

European journal of clinical microbiology & infectious diseases, 2024-03, Vol.43 (3), p.541-550

2024

Volltextzugriff (PDF)

Reply by Authors

The Journal of urology, 2021-03, Vol.205 (3), p.832-832

2021

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(55)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Unbiased identification of risk factors for invasive Escherichia coli disease using machine learning

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Tutorial in biostatistics: the self-controlled case series method

Distribution of extraintestinal pathogenic Escherichia coli O-serotypes and antibiotic resistance in blood isolates collected from patients in a surveillance study in Japan

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Harmonizing the collection of solicited adverse events in prophylactic vaccine clinical trials

A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

A Nurse-Led Interdisciplinary Intervention Program for Delirium in Elderly Hip-Fracture Patients

Adjusted significance levels for subgroup analyses in clinical trials

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Testing Treatment Effect in Randomized Clinical Trials With Possible Nonproportional Hazards

Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic Escherichia coli Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies

Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60 to 85 years in a randomized, double-blind, phase 1 study

Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections

Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study

Reply by Authors

Suchergebnisse filtern